May 17, 2020

Robotechnology forcing anesthesiologists out of a job, absorbing malpractice costs

Admin
3 min
Robotechnology forcing anesthesiologists out of a job, absorbing malpractice costs.jpg
I think we can all agree that if robotechnology is anything like Will Smiths experience in I Robot, then Im not sure how ready our public is for what r...

I think we can all agree that if robotechnology is anything like Will Smith’s experience in I Robot, then I’m not sure how ready our public is for what robotechnology has to offer. Would you trust a robot, or better yet, a robodoctor with your life?

With the upcoming implementation of robotechnology in hospitals around the globe, more and more hospital workers are feeling the tension from these robodoctors taking away their patients and their jobs. The jury is still out concerning whether or not robots are qualified in making life-or-death medical decisions, an area where being human certainly helps when it comes to making split-second, life-saving decisions for a patient. Hospitals have been utilizing the robotechnology in low-stakes procedures like colonoscopies, using the robodoctors to administer anesthesia to patients. How do anesthesiologists feel about robodoctors doing their jobs? More importantly, how do we feel about robodoctors doing their jobs, regardless if the procedures are low-stakes or not?

“Another possibility is that this will work as well as, or better than, a doctor and replaces anesthesiologists -- not just for colonoscopies, but for more and more procedures. The health-care cost curve bends, and a bunch of doctors lose a very good living’, says Megan McArdle of the Huffington Post.

The ethical issue remains: who is accountable is a mistake is made by a robot during a surgical procedure? Administering anesthesia? Or worse?

Anesthesiology, which requires a huge amount of manual labor and on-point decision making skills, strikes me as something which robots don’t have. However, on the opposite end of the polarized debate, an anesthesiologist is not a necessary position; it drastically helps patient comfort, but does not impact the survival rate of the patient.

With all of the talk about the proponents of this technology and what good it can bring, the public questions the issue of malpractice, and how it will impact businesses mal practice costs. Some argue it the responsibility of the manufacturer of the robodoctor if the machine malfunctions and that they should absorb the costs, thus removing the expensive malpractice costs from hospital budgets. Others argue that it is the responsibility of the clinician overseeing the robodoctor who needs to step-up and assume responsibility, putting extra pressure and the cost back onto that hospital worker, now being responsible for someone else’s actions. Regardless of who the blame falls onto, how do patients feel about a robot being in control of their pain-level, or more importantly, their life?

Companies like Johnson & Johnson and Dignity Health are considering implementing the anesthesiology robodoctors and general robotechnology, believing it may do more good than harm to the public’s healthcare needs.

“Johnson & Johnson proposes to replace anesthesiologists during simple procedures such as colonoscopies -- not with nurse practitioners, but with machines. Sedasys, which dispenses propofol and monitors a patient automatically, was recently approved for use in healthy adult patients who have no particular risk of complications. Johnson & Johnson will lease the machines to doctor’s offices for $150 per procedure -- cleverly set well below the $600 to $2,000 that anesthesiologists usually charge” says the Huffington Post.

Another company investing in the technology is Dignity Health, which runs Arizona, California and Nevada hospitals. This technology  began using the telemedicine machines five years ago to diagnose patients suspected of suffering strokes — when every minute is crucial to prevent serious brain damage.

“Regardless of where the patient is located, we can be at their bedside in several minutes," said Dr. Alan Shatzel, medical director of the Mercy Telehealth Network. "Literally, we compress time and space with this technology. No longer does distance affect a person's ability to access the best care possible.”

 

About the Author

Alyssa Clark is the Editor of Healthcare Global

 

 

 

Share article

Jun 16, 2021

NHS opens 8 clinical trial sites to assess cancer treatment

NHS
Cancer
immunotherapy
MachineLearning
2 min
NHS and OncoHost to launch clinical trials analysing cancer patients response to immunotherapy

The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy. 

The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment.  They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities. 

Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.

OncoHost, an oncology startup,  will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®

“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.

“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient." 

"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”

Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.

Share article